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DEVELOPMENT OF AN ANALYTICAL PLATFORM FOR DELIVERY OF RECOMBINANT ONCOLYTIC 
VIRUSES 
 




Over the past two decades, a number of modified DNA and RNA viruses have shown great promise in cancer 
therapy. Their tumor specific cytotoxic activity involves several mechanisms. These include preferential uptake 
and replication of the virus in cancer cells, followed by infection and lysis of these cells (oncolysis). In addition, 
oncolytic viruses (OV), especially those engineered with appropriate transgenes, have been shown to induce 
tumor specific immune responses, thereby opening up an exciting area of cancer immunotherapy. 
 
One OV, containing a recombinant Herpes Simplex Virus (HSV) with a Granulocyte Macrophage Colony 
Stimulating Factor (GMCSF) transgene insert, was approved in 2015 for treatment of refractory melanoma. 
While this drug, known as T-Vec or Imlygic, is administered intratumorally, several other OVs are in pre-clinical 
and clinical development with intravenous (IV) administration as an objective. The IV route potentially offers the 
advantages of accessing metastatic sites and eliciting systemic immunotherapeutic response. A recombinant 
form of the Newcastle Disease Virus (rNDV) has been recently developed that also incorporates GMCSF as a 
transgene.  NDV is a single stranded, negative sense, enveloped RNA virus and, in native form, is not a human 
but an avian pathogen. Genetic engineering was performed to reduce avian pathogenicity and increase 
immunotherapeutic potential against cancer [1]. In addition to lysis of cancer cells produced by viral infection, 
rNDV has demonstrated induction of cytokine and chemokine responses, cell infiltration and long - term 
suppression of tumor growth in animal models. 
 
Production of recombinant viruses requires selection of appropriate host cells, based on considerations of yield 
and quality of the product.  In recent years, regulatory agencies have been open to use of human cell lines as 
host, including some tumor derived cells, such as HeLa.  An advantage offered by HeLa cells is potential 
incorporation into the virus of host proteins known as regulators of complement activation (RCA). This allows a 
longer half-life of the virus in circulation.  However, impurities derived from host cells as well as process 
conditions must be kept to the lowest levels possible.  A thorough analytical and biophysical evaluation of the 
purified virus particles includes measurements of (a) infectivity, (b) morphology, (c) size distribution, (c) genetic 
integrity, and (d) major viral proteins. In addition, levels of contaminants such as residual host cell proteins and 
DNA must be evaluated, including sizes of residual DNA fragments.  Robust and accurate measurement of 
infectious titer is especially important as this determines doses of an OV to be delivered to patients. It also 
provides a measure of virus stability and is critical to supporting process development. We have optimized a 
Fluorescent Focus Assay (FFA) that produces concordant results with Plaque Assay (PA) over several orders of 
magnitude of infectious titers [2]. FFA provides a faster turn-around in a higher throughput format compared to 
PA.  These and additional structure-function assays were developed to support process development and 
deliver a well-characterized OV for cancer immunotherapy.  
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